Abstract
This review confirms the findings from randomized trials regarding the risk of cardiovascular events with rofecoxib and suggests that celecoxib in commonly used doses may not increase the risk, contradicts claims of a protective effect of naproxen, and raises serious questions about the safety of diclofenac, an older drug.
Keywords
MedicineRofecoxibRelative riskCelecoxibInternal medicineMyocardial infarctionConfidence intervalCohort studyDiclofenacCyclooxygenaseObservational studyCohortPharmacology
Affiliated Institutions
Related Publications
Fluorophore‐Labeled Cyclooxygenase‐2 Inhibitors for the Imaging of Cyclooxygenase‐2 Overexpression in Cancer: Synthesis and Biological Studies
Abstract A group of cyclooxygenase‐2 (COX‐2)‐specific fluorescent cancer biomarkers were synthesized by linking the anti‐inflammatory drugs ibuprofen, ( S )‐naproxen, and celeco...
Medroxyprogesterone Acetate Antagonizes Inhibitory Effects of Conjugated Equine Estrogens on Coronary Artery Atherosclerosis
Although estrogen replacement therapy is associated with reduced risk of coronary heart disease and reduced extent of coronary artery atherosclerosis, the effects of combined (e...
Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis
Objectives: Corticosteroids may be beneficial in sepsis, but uncertainty remains over their effects in severe influenza. This systematic review updates the current evidence rega...
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee
BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine ha...
Secondary prevention of vascular disease by prolonged antiplatelet treatment
Thirty one randomised trials of antiplatelet treatment for patients with a history of transient ischaemic attack, occlusive stroke, unstable angina, or myocardial infarction wer...
Publication Info
- Year
- 2006
- Type
- review
- Volume
- 296
- Issue
- 13
- Pages
- 1633-1633
- Citations
- 1097
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
1097
OpenAlex
Cite This
Patricia McGettigan,
David Henry
(2006).
Cardiovascular Risk and Inhibition of Cyclooxygenase.
JAMA
, 296
(13)
, 1633-1633.
https://doi.org/10.1001/jama.296.13.jrv60011
Identifiers
- DOI
- 10.1001/jama.296.13.jrv60011